370 related articles for article (PubMed ID: 31748536)
1. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
van Dessel LF; van Riet J; Smits M; Zhu Y; Hamberg P; van der Heijden MS; Bergman AM; van Oort IM; de Wit R; Voest EE; Steeghs N; Yamaguchi TN; Livingstone J; Boutros PC; Martens JWM; Sleijfer S; Cuppen E; Zwart W; van de Werken HJG; Mehra N; Lolkema MP
Nat Commun; 2019 Nov; 10(1):5251. PubMed ID: 31748536
[TBL] [Abstract][Full Text] [Related]
2. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Viswanathan SR; Ha G; Hoff AM; Wala JA; Carrot-Zhang J; Whelan CW; Haradhvala NJ; Freeman SS; Reed SC; Rhoades J; Polak P; Cipicchio M; Wankowicz SA; Wong A; Kamath T; Zhang Z; Gydush GJ; Rotem D; ; Love JC; Getz G; Gabriel S; Zhang CZ; Dehm SM; Nelson PS; Van Allen EM; Choudhury AD; Adalsteinsson VA; Beroukhim R; Taplin ME; Meyerson M
Cell; 2018 Jul; 174(2):433-447.e19. PubMed ID: 29909985
[TBL] [Abstract][Full Text] [Related]
3. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
[TBL] [Abstract][Full Text] [Related]
4. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Quigley DA; Dang HX; Zhao SG; Lloyd P; Aggarwal R; Alumkal JJ; Foye A; Kothari V; Perry MD; Bailey AM; Playdle D; Barnard TJ; Zhang L; Zhang J; Youngren JF; Cieslik MP; Parolia A; Beer TM; Thomas G; Chi KN; Gleave M; Lack NA; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Ryan CJ; Fong L; Kim W; Friedlander T; Chou J; Li H; Das R; Li H; Moussavi-Baygi R; Goodarzi H; Gilbert LA; Lara PN; Evans CP; Goldstein TC; Stuart JM; Tomlins SA; Spratt DE; Cheetham RK; Cheng DT; Farh K; Gehring JS; Hakenberg J; Liao A; Febbo PG; Shon J; Sickler B; Batzoglou S; Knudsen KE; He HH; Huang J; Wyatt AW; Dehm SM; Ashworth A; Chinnaiyan AM; Maher CA; Small EJ; Feng FY
Cell; 2018 Jul; 174(3):758-769.e9. PubMed ID: 30033370
[TBL] [Abstract][Full Text] [Related]
5. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
6. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
8. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
Lin E; Hahn AW; Nussenzveig RH; Wesolowski S; Sayegh N; Maughan BL; McFarland T; Rathi N; Sirohi D; Sonpavde G; Swami U; Kohli M; Rich T; Sartor O; Yandell M; Agarwal N
Oncologist; 2021 Sep; 26(9):751-760. PubMed ID: 34157173
[TBL] [Abstract][Full Text] [Related]
9.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
11. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
12. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.
Nava Rodrigues D; Casiraghi N; Romanel A; Crespo M; Miranda S; Rescigno P; Figueiredo I; Riisnaes R; Carreira S; Sumanasuriya S; Gasperini P; Sharp A; Mateo J; Makay A; McNair C; Schiewer M; Knudsen K; Boysen G; Demichelis F; de Bono JS
Clin Cancer Res; 2019 Jan; 25(2):687-697. PubMed ID: 30257982
[TBL] [Abstract][Full Text] [Related]
13. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR
Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703
[TBL] [Abstract][Full Text] [Related]
14. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
[TBL] [Abstract][Full Text] [Related]
15. Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
Barnett ES; Schultz N; Stopsack KH; Lam ET; Arfe A; Lee J; Zhao JL; Schonhoft JD; Carbone EA; Keegan NM; Wibmer A; Wang Y; Solit DB; Abida W; Wenstrup R; Scher HI
Eur Urol; 2023 Feb; 83(2):112-120. PubMed ID: 36123219
[TBL] [Abstract][Full Text] [Related]
16. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
Chen WS; Aggarwal R; Zhang L; Zhao SG; Thomas GV; Beer TM; Quigley DA; Foye A; Playdle D; Huang J; Lloyd P; Lu E; Sun D; Guan X; Rettig M; Gleave M; Evans CP; Youngren J; True L; Lara P; Kothari V; Xia Z; Chi KN; Reiter RE; Maher CA; Feng FY; Small EJ; Alumkal JJ;
Eur Urol; 2019 Nov; 76(5):562-571. PubMed ID: 30928160
[TBL] [Abstract][Full Text] [Related]
17. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
18. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
19. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
20. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
